| Date | Title | | | 05/09/12 | Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update| ROCKVILLE, Md., May 9, 2012 /PRNewswire via COMTEX/ --Neuralstem, Inc. (NYSE Amex: CUR) today reported its financial results for the three months ended March 31, 2012 and provided a business and clinical update.
(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )
"In the first Quarter of 2012, we entered the final cohort of our Phase I clinical trial in ALS at Emory University Hospital. We are encouraged with the recent approval by the FDA to amend the trial protocol to bring... |
| | | 05/08/12 | Neuralstem Updates ALS Stem Cell Trial Progress| FDA Permits Additional Dosing of Return Patients
ROCKVILLE, Md., May 8, 2012 /PRNewswire via COMTEX/ --Neuralstem, Inc. (NYSE Amex: CUR) announced that the Food and Drug Administration (FDA) has approved the return of three patients from earlier cohorts in its ongoing Phase I safety trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells (HSSC's). These patients will be permitted to return to the trial for second treatments as the next co... |
| | | 04/25/12 | Neuralstem Chief Scientific Officer To Present At Spinal Cord Injury Conference In China| ROCKVILLE, Md., April 25, 2012 /PRNewswire via COMTEX/ --Neuralstem, Inc. (NYSE Amex: CUR) announced that Karl Johe, PhD, Chairman and Chief Scientific Officer, will present at the Fourth International Spinal Cord Injury Treatments and Trials Symposium, in Xi'an, China on Friday, May 4, at 1:00 PM (http://iscitt.org/iscitt4/). Dr. Johe's talk, entitled "Human spinal cord-derived neural stem cells (HSSC) for treatment of neurological diseases," will review the readiness of Neuralstem's cells to e... |
| | | 03/29/12 | Neuralstem Announces 2011 Financial Results, Provides Operations Update| table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} ROCKVILLE, Maryland, March 29, 2012 - Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and operations update for the year ended December 31, 2011. "2011 was another year of steady progress for Neuralstem. U.S. clinical trials progressed in both our cell therapy and pharmaceutical divisions, with consistently positive and encouraging human safety data. That data covered neural stem cell transplant... |
|  |
|
